FIELD: medicine, pharmaceutics.
SUBSTANCE: what is offered is application of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinamidoxime or its pharmaceutically acceptable salt for preparing a pharmaceutical composition applicable for preventing or reducing a side effect represented by overweight or obesity in treating by an antipsychotic drug, and the pharmaceutical composition possess said action and contains the antipsychotic agent which when taken causes overweight or obesity, and O-(3-piperidino-2-hydroxy-1-propyl)-nicotinamidoxime or its pharmaceutically acceptable salt mixed with more than one common carrier.
EFFECT: reducing the declared side effect ensured by olanzapine, clozapine and risperidon is shown with metformin and rosiglitazone failed to prevent olanzapine-induced weight gain.
8 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OVERWEIGHT OR OBESITY REDUCTION | 2007 |
|
RU2443417C2 |
| NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS FOR TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | 1998 |
|
RU2222330C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR, AND THEIR USE | 2015 |
|
RU2757221C2 |
| DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B, E] [1, 4] DIAZEPINE AND THEIR APPLICATION | 2014 |
|
RU2610169C2 |
| THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
| MIXTURE CONTAINING CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF SCHIZOPHRENIA | 2018 |
|
RU2772465C2 |
| AZENAPIN FOR TREATMENT OF SCHIZOPHRENIA AT PATIENTS WITH OVERWEIGHT OR PREDISPOSITION TO OVERWEIGHT | 2004 |
|
RU2352336C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FUNCTIONAL MENTAL DISORDERS | 2016 |
|
RU2667954C2 |
| CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR PHRENOPATHY TREATMENT | 2003 |
|
RU2356554C2 |
| CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATING PHRENOPATHIES | 2008 |
|
RU2389490C2 |
